Codexis pairs up to take new treatments from discovery to market

摘要

Phenylketonuria (PKU) is a genetic condition that causes intellectual disability when left untreated and treatment typically imposes a very restricted, life-long diet. New treatments stand to revolutionise outcomes for this condition as, by the time people with PKU reach adulthood, typically only 10% are sticking with the recommended, demanding diet. In an example of how collaborative thinking can benefit patients, protein engineering expert, Codexis, has teamed up with pharmaceutical marketing giant, Nestle Health Science, to develop an oral treatment for phenylketonuria (PKU).Another rare disease, Fabry disease, causes problems in the heart and kidney and, left untreated, can greatly reduce life expectancy. To generate a better treatment option for Fabry patients, Codexis is working with Takeda to generate better versions of the enzyme whose activity is missing in these patients, for administration as gene therapy.